USA 114 , E75E84 (2017)
How the study was designed Included adults 18 to 65 with type 2 diabetes who were newly prescribed one of three drug types: a GLP-1 receptor agonist (161,489 people), an SGLT-2 inhibitor (122,114 people), or a DPP-4 inhibitor (86,047 people)
But only one approach will leave you stronger, healthier, and more capable of maintaining your results.
Microdosing GLP-1 for Autoimmune Conditions According to a comprehensive systematic review published in 2024, treatment with GLP-1 receptor agonists results in significant reductions in disease severity among patients with psoriasis
Establish a follow-up schedule to track weight, metabolic parameters, and overall health
Over time, frequent NSAID use can place a higher demand on glutathione reserves, leading to depletion